bluebird bio Stock Forecast NASDAQ:BLUE

Price Target and Analyst Ratings

Most Recent Rating

On August 10, 2021 "Mizuho" gave "$70.00 - $29.00" rating for BLUE. The price target was set to $19.73+8.6%.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-08-10	$70.00 - $29.00	Target Lowered by	Mizuho	$20.04	$19.73+8.6%
2021-08-10	$60.00 - $25.00	Downgraded by	Wells Fargo & Company	$20.04	$18.16→27.4%
2021-08-10	$70.00 - $29.00	Reiterated by	Mizuho	$20.04	$18.16→27.4%
2021-08-10	$41.00 - $22.00	Target Lowered by	Bank of America	$20.04	$19.73+8.6%
2021-08-10	$63.00 - $23.00	Downgraded by	The Goldman Sachs Group	$20.04	$18.16→27.4%
2021-08-10	$86.00 - $20.00	Downgraded by	Canaccord Genuity	$20.04	$18.90+4.1%
2021-08-10	$29.00 - $21.00	Target Lowered by	BMO Capital Markets	$20.04	$19.73+8.6%
2021-08-09	$31.00 - $18.00	Target Lowered by	Stifel Nicolaus	$18.16	$18.15→27.5%
2021-08-09		Downgraded by	SVB Leerink	$18.16	$18.78→25.0%
2021-08-01		Reiterated by	SVB Leerink	$25.41	$25.410.0%
2021-07-16	$36.00 - $35.00	Target Lowered by	Morgan Stanley	$26.78	$27.46→0.3%
2021-07-01	Buy - Hold	Downgraded by	Berenberg Bank	$32.42	$35.00
2021-06-15	Hold	Reiterated by	Oppenheimer	$32.83
2021-06-10	Buy	Initiated by	SVB Leerink	$33.89
2021-04-26	Equal Weight	Target Lowered by	Morgan Stanley	$29.48	$45.00 → $36.00
2021-04-21	Market Perform	Target Lowered by	BMO Capital Markets	$28.12	$35.00 → $31.00
2021-04-19	Equal Weight	Target Lowered by	Morgan Stanley	$27.98	$45.00 → $36.00
2021-03-29	Buy	Reiterated by	Jefferies Financial Group	$30.94
2021-03-29	Market Perform	Target Raised by	BMO Capital Markets	$30.94	$31.00 → $35.00
2021-03-29		Target Raised by	Piper Sandler	$30.94	$30.00 → $35.00
2021-03-29	Outperform	Target Raised by	SVB Leerink	$30.94	$69.00 → $72.00
2021-03-28	Hold	Reiterated by	Oppenheimer	$29.98
2021-03-16	Neutral - Buy	Upgraded by	Mizuho	$32.39	$34.00 → $69.00
2021-03-14	Buy	Reiterated by	SVB Leerink	$32.43
2021-03-10		Target Raised by	Stifel Nicolaus	$32.48	$26.00 → $31.00
2021-03-10	Neutral - Buy	Upgraded by	Mizuho	$32.48	$34.00 → $69.00
2021-03-08	Equal Weight	Target Lowered by	Morgan Stanley	$28.25	$50.00 → $45.00
2021-03-02	Equal Weight	Target Lowered by	Morgan Stanley	$30.80	$50.00 → $45.00
2021-02-24	Equal Weight	Target Lowered by	Barclays	$25.92	$31.00 → $27.00
2021-02-17	Market Perform	Target Raised by	BMO Capital Markets	$28.02	$36.00 → $56.00
2021-02-17	Hold	Target Lowered by	Stifel Nicolaus	$28.02	$48.00 → $35.00
2021-02-17	Overweight - Neutral	Downgraded by	JPMorgan Chase & Co.	$28.02	$76.00 → $39.00
2021-02-17	Outperform - Sector Perform	Downgraded by	Royal Bank of Canada	$28.02
2021-02-16	Outperform - Market Perform	Downgraded by	Oppenheimer	$28.44
2021-02-16	Buy - Neutral	Downgraded by	Bank of America	$28.44
2021-02-16	Outperform - Neutral	Downgraded by	Wedbush	$28.44
2021-02-16	Outperform - Market Perform	Downgraded by	William Blair	$28.44
2021-02-16	Neutral	Target Lowered by	Piper Sandler	$28.44	$55.00 → $35.00
2021-02-16	Buy - Neutral	Downgraded by	Mizuho	$28.44
2020-12-09	Buy - Hold	Downgraded by	Maxim Group	$42.61
2020-12-07	Buy	Reiterated by	Mizuho	$45.40
2020-11-11	Buy	Initiated by	Berenberg Bank	$45.48
2020-11-11	Equal Weight	Target Lowered by	Morgan Stanley	$45.48	$68.00 → $50.00
2020-11-06	Outperform	Target Lowered by	Wedbush	$45.89	$81.00 → $73.00
2020-11-05	Buy - Hold	Downgraded by	Stifel Nicolaus	$48.83	$77.00 → $51.00
2020-11-05	Outperform	Target Lowered by	Oppenheimer	$48.83	$111.00 → $90.00
2020-11-05	Outperform	Target Lowered by	Royal Bank of Canada	$48.83	$100.00 → $93.00
2020-11-05	Buy	Target Lowered by	Bank of America	$48.83	$100.00 → $81.00
2020-11-05	Outperform	Target Lowered by	SVB Leerink	$48.83	$133.00 → $99.00
2020-11-05	Overweight - Equal Weight	Downgraded by	Barclays	$48.83
2020-11-05	Overweight	Target Lowered by	JPMorgan Chase & Co.	$48.83	$140.00 → $76.00
2020-11-05	Overweight	Target Lowered by	Wells Fargo & Company	$48.83	$94.00 → $81.00
2020-11-05	Buy	Target Lowered by	Canaccord Genuity	$48.83	$118.00 → $86.00
2020-11-05	Outperform - Market Perform	Downgraded by	BMO Capital Markets	$48.83	$108.00 → $56.00
2020-11-04	Neutral	Target Lowered by	Piper Sandler	$58.55	$70.00 → $55.00
2020-11-02	Market Perform - Outperform	Upgraded by	William Blair	$53.09
2020-10-19	Buy	Initiated by	Mizuho	$54.55	$123.00
2020-10-19	Buy	Initiated by	Mizuho	$54.55
2020-08-31	Buy	Initiated by	Oppenheimer	$59.30	$111.00
2020-08-30	Hold	Reiterated by	William Blair	$56.75
2020-08-19	Buy	Reiterated by	JPMorgan Chase & Co.	$60.95
2020-08-10	Equal Weight	Target Lowered by	Morgan Stanley	$65.77	$73.00 → $68.00
2020-08-06	Outperform	Target Lowered by	BMO Capital Markets	$63.84	$112.00 → $108.00
2020-08-06	Outperform	Target Lowered by	Wedbush	$63.84	$89.00 → $81.00
2020-07-29	Buy	Initiated by	Oppenheimer	$62.34	$111.00
2020-07-13	Buy	Target Lowered by	Bank of America	$60.71	$104.00 → $100.00
2020-06-12	Outperform	Target Raised by	SVB Leerink	$63.93	$129.00 → $133.00
2020-06-01	Buy	Initiated by	Oppenheimer	$64.38	$111.00
2020-05-28	Outperform	Target Raised by	SVB Leerink	$60.81	$125.00 → $129.00
2020-05-28	Equal Weight	Target Raised by	Morgan Stanley	$60.81	$69.00 → $73.00
2020-05-13	Buy	Reiterated by	Barclays	$55.82
2020-05-12	Outperform	Target Raised by	BMO Capital Markets	$56.86	$107.00 → $112.00
2020-05-12	Outperform	Initiated by	Royal Bank of Canada	$56.86
2020-05-12	Buy	Reiterated by	Canaccord Genuity	$56.86	$118.00
2020-05-11	Neutral	Target Lowered by	Piper Sandler	$60.23	$75.00 → $70.00
2020-04-15	Equal Weight	Target Lowered by	Morgan Stanley	$47.37	$92.00 → $69.00

BLUE Stock Trend

Given the current short-term trend, the stock is expected to fall -51.39% during the next 3 months and, with a 90% probability hold a price between $5.70 and $8.59 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-20	$11.43	$14.40	$17.38
2021-09-21	$11.13	$14.11	$17.09
2021-09-22	$10.83	$13.81	$16.79
2021-09-23	$10.54	$13.51	$16.49
2021-09-24	$10.24	$13.22	$16.20
2021-09-27	$9.94	$12.92	$15.90
2021-09-28	$9.65	$12.62	$15.60
2021-09-29	$9.35	$12.33	$15.31
2021-09-30	$9.05	$12.03	$15.01
2021-10-01	$8.76	$11.73	$14.71
2021-10-04	$8.46	$11.44	$14.42
2021-10-05	$8.16	$11.14	$14.12
2021-10-06	$7.87	$10.84	$13.82
2021-10-07	$7.57	$10.55	$13.53
2021-10-08	$7.27	$10.25	$13.23
2021-10-11	$6.98	$9.95	$12.93
2021-10-12	$6.68	$9.66	$12.64
2021-10-13	$6.38	$9.36	$12.34
2021-10-14	$6.09	$9.06	$12.04
2021-10-15	$5.79	$8.77	$11.75
2021-10-18	$5.49	$8.47	$11.45
2021-10-19	$5.20	$8.17	$11.15
2021-10-20	$4.90	$7.88	$10.86
2021-10-21	$4.60	$7.58	$10.56
2021-10-22	$4.31	$7.28	$10.26
2021-10-25	$4.01	$6.99	$9.97
2021-10-26	$3.71	$6.69	$9.67
2021-10-27	$3.42	$6.39	$9.37
2021-10-28	$3.12	$6.10	$9.08
2021-10-29	$2.82	$5.80	$8.78

About bluebird bio

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its product candidates include Lenti-D, which is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell di... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!